With the advent of widespread screening of prostate-specific antigen (PSA) testing, increasing number of males have been diagnosed with prostate cancer (PCa). Cancer statistics of the United States estimated that there were about 233,000 newly diagnosed PCa patients in 2014, with 29,480 patients succumbing to the disease, PCa was the most frequent cause for morbidity and the second most common cause for mortality in males[@b1].

Traditionally, although multiple choices were available, including watchful waiting/active surveillance, castration, radical prostatectomy (RP), radiotherapy (RT), chemotherapy and minimally invasive treatments, an appropriate treatment choice for PCa has remained uncertain and controversial over a long period[@b2]. However, considering the deficiencies in radical therapies (RP and RT), minimally invasive treatments have been gradually adopted. To date, several minimally invasive treatments have been applied to PCa, among which ablative CS is the most widely chosen.

CS was first applied into PCa in 1964 and had undergone several modifications[@b3], which have made it more effective in both primary and salvage therapy. However, it has been prevalent mainly in the previous two decades. This operation is accomplished by destroying the prostate by inducing the formation of intracellular ice with an extremely low temperature under the guidance of imaging; the freezing triggers cellular apoptosis and the inflammatory cascade[@b4]. Several studies aimed at evaluating the efficiency and safety of cryosurgery for PCa have been carried out, but have demonstrated conflicting results.

In this study, we aim to obtain more definitive results by evaluating and comparing the potential benefits and complications of CS with those of RP/RT, and comprehensively reviewing the available literature.

Results
=======

Meta-analysis
-------------

In total, 10 papers from seven studies with 1252 patients (561 for CS vs RT, 745 for CS vs RP and 54 for both) were finally included for pooling in our study[@b5][@b6][@b7][@b8][@b9][@b10][@b11][@b12][@b13][@b14] ([Fig. 1](#f1){ref-type="fig"}). The characteristics of each study are summarized in [Table 1](#t1){ref-type="table"}.

Seven papers[@b5][@b6][@b7][@b8][@b9][@b10][@b11] from five studies reported the comparison between CS and RT, from which two articles[@b7][@b8] based on one study presented results in mean follow-ups of 37 months and 105.2 months, respectively, results from one study were presented simultaneously in two papers[@b9][@b10]. Both these studies were RCTs. One study was prospective[@b5] and two studies were retrospective[@b6][@b11]. Three studies were also conducted for primary treatment of PCa, one[@b11] for salvage treatment after primary RT and one for both primary and salvage treatments[@b5]. Only one study had provided available materials for both comparisons[@b11].

For comparison between CS and RP, a total of four studies[@b11][@b12][@b13][@b14] were involved in the analysis, of which one was prospective whereas three were retrospective. Furthermore, two studies each revealed the results of primary[@b12][@b14] and salvage[@b11][@b13] procedures. One study[@b12] described two CS methods, total and subtotal, which were summed into the CS group, whereas similar summation was used in another study[@b14] for the RP group.

Primary Outcomes
----------------

### Overall survival (OS)

Four studies[@b8][@b10][@b11][@b13] including a total of 494 patients, three publications[@b8][@b10][@b11] with 378 patients evaluating CS vs RT and two[@b11][@b13] publications with 170 patients evaluating CS vs RP (including one study[@b11] reported both) assessed OS; of these, two studies[@b11][@b13] had focused on salvage treatment. Data revealed a tendency for an advantage in the CS group, but insignificant differences (RR 1.16, 95% CI 0.82--1.64, p = 0.40, and RR 1.05, 95% CI 0.75--1.48, p = 0.76, respectively) ([Fig. 2a](#f2){ref-type="fig"}).

### Disease specific survival (DSS)

These four studies had also reported DSS, which demonstrated similar results to OS (RR 1.15, 95% CI 0.78--1.72, p = 0.48 in CS vs RT and RR 1.06, 95% CI 0.92--1.21, p = 0.44 in CS vs RP) ([Fig. 2b](#f2){ref-type="fig"}).

### Disease-free survival (DFS)

Data describing DFS were pooled from six studies[@b8][@b10][@b11][@b12][@b13][@b14], of which three[@b8][@b10][@b11] with 226 patients evaluated CS vs RT whereas four[@b11][@b12][@b13][@b14] with 688 cases regarding CS vs RP, including one study[@b11] reporting three kinds of treatments. However, comparing OS and DSS, opposite tendencies were presented in both comparisons, in which significant differences could not be found in CS vs RT (RR 0.69, 95% CI 0.32--1.49, p = 0.35) but in CS vs RP (RR 0.85, 95% CI 0.73--0.99, p = 0.03) ([Fig. 2c](#f2){ref-type="fig"}).

Secondary outcomes
------------------

In total, three publications[@b5][@b6][@b9] of evaluating CS vs RT had provided available data for pooling, from which only six patients in one study[@b5] received salvage cryosurgery. Furthermore, these three publications dynamically (two with continuous variables and one with dichotomous variables) described follow-up in multiple stages: urinary and sexual bothers in months 1, 3, 6, 12 and 24 were extracted for analysis.

### Urinary bother

According to UCLA PCI scores, pooled data from continuous variables of two studies[@b5][@b6] revealed that there was no significant difference in each stage, but slightly lower scores were observed in the RT group in months 12 and 24 (WMD 13.00, 95% CI −7.01--33.01, p = 0.20 and WMD 12.00, 95% CI −9.86--33.86, p = 0.28, respectively) ([Fig. 3](#f3){ref-type="fig"}). However, differences between 1.5 and 3 months were significant in the dichotomous variable of one study[@b9] (RR 8.09, 95% CI 2.01--32.58, p = 0.003; and RR 2.99, 95% CI 1.16--7.73, p = 0.02) ([Fig. 4](#f4){ref-type="fig"}).

### Sexual bother

Compared with RT group, the CS group presented tendencies of lower UCLA PCI scores for sexual bother at all stages, including a significantly lower score in the six month (WMD −16.13, 95% CI −30.55 to −1.70, p = 0.03) ([Fig. 5](#f5){ref-type="fig"}). Similarly, significantly more sexual bother were presented in the CS group at all stages than the RT group (RR 1.84, 95% CI 1.25--2.73, p = 0.002 in month 1.5; RR 2.25, 95% CI 1.55--3.27, p \< 0.0001 at 3 months; RR 1.66, 95% CI 1.20--2.29, p = 0.002 at 6 months; RR 1.68, 95% CI 1.20--2.34, p = 0.002 at 12 months and RR 1.63, 95% CI 1.18--2.26, p = 0.003 at 24 months).

### Biopsy Positivity and cancer metastasis

Two publications[@b8][@b10] reported no significant difference in the number of positive biopsies after primary treatments of CS and RT (RR 0.54, 95% CI 0.13--2.33, p = 0.41). A similar result was found in cancer metastasis (RR 0.67, 95% CI 0.12--3.72, p = 0.64).

### Sensitivity analysis and publication bias

Only two RCTs regarding CS vs RT were retained for sensitivity analysis, which revealed nearly equal OS (RR 1.0, 95% CI 0.91--1.11, p = 0.96) and DSS (RR 0.99, 95% CI 0.92--1.07, p = 0.86), and equivalent rates of biopsy positivity and metastasis and complications. A trend favoring RT (but without significance) was evident (RR 0.60, 95% CI 0.11--3.21, p = 0.55). No RCT was available for comparing CS vs RP.

Systematic Review
-----------------

### Comparisons from databases

During our searches, five publications[@b15][@b16][@b17][@b18][@b19] based on two databases were extracted, of which one study was carried out on the basis of the Cancer of the Prostate Strategic Research Endeavor (CaPSURE) registry whereas the other four studies were from Surveillance Epidemiology and End Results (SEER)-Medicare linked database. Basic information about these studies is summarized in [Table 2](#t2){ref-type="table"}.

The CaPSURE registry was used by White *et al*.[@b15] to evaluate the quality of life in patients with T3 or T4 PCa, and revealed significant decreases in urinary and sexual function according to UCLA PCI scores after treatment. Similar differences in urinary and sexual function could also be found between types of treatment; however, data for further analysis was unavailable.

Four publications[@b16][@b17][@b18][@b19] reported outcomes on the basis of the SEER-Medicare linked database, of which three studies[@b16][@b17][@b19] concentrated on primary treatments whereas the remaining study[@b18] focused on salvage treatments. According to Williams' study[@b16], there were significantly higher overall complications, urinary complications and ED in the CS group than those in the RT group (RR 1.33, 95% CI 1.27--1.40, p \< 0.00001 for overall complications; RR 1.77, 95% CI 1.62--1.93, p \< 0.00001 for urinary complications; and RR 1.59, 95% CI 1.45--1.75, p \< 0.00001 for ED).

In addition, Roberts *et al*.[@b17] reported that \>28.7% of patients experienced urinary complications and 20.1% ED, after CS. Moreover, in a study by Jarosek *et al*., urinary complication incidence of 19.4%, 19.7% and 27.2% was reported in CS, RT and RP groups, respectively (RR 9.84, 95% CI 8.89--10.89, p \< 0.00001 for CS vs RT; RR 0.71, 95% CI 0.65--0.78, p \< 0.00001 for CS vs RP) (EBRT, BT and their combination were regarded as the RT group). Only one study[@b18] for salvage treatments presented an OS of 93.9% vs 78.4% (p = 0.001) and a DSS of 98.6% vs 93.5% (p = 0.07) for CS vs RP.

Furthermore, two studies[@b16][@b18] carried out an economic analysis and revealed significantly lower costs in the CS group than both the RT group and the RP group.

### Data from single-arm studies

Twenty-eight publications[@b20][@b21][@b22][@b23][@b24][@b25][@b26][@b27][@b28][@b29][@b30][@b31][@b32][@b33][@b34][@b35][@b36][@b37][@b38][@b39][@b40][@b41][@b42][@b43][@b44][@b45][@b46][@b47], which had reported availably single-arm results of CS treatment for clinically localized PCa, were screened. Sixteen[@b23][@b24][@b25][@b26][@b29][@b30][@b31][@b33][@b34][@b36][@b38][@b41][@b42][@b45][@b46][@b47] of these papers had presented outcomes for primary therapy, eight[@b20][@b22][@b27][@b28][@b32][@b35][@b40][@b43] for salvage therapy following RT, one[@b44] for salvage therapy following primary CS, and three[@b21][@b37][@b39] for both therapies. In addition, materials from the Cryo On-Line Data Registry were used in four publications[@b30][@b40][@b45][@b46]. Basic information and results of each study are summarized in [Table 3](#t3){ref-type="table"}.

### Primary outcomes

Eighteen studies[@b21][@b22][@b24][@b25][@b28][@b29][@b32][@b34][@b35][@b36][@b37][@b38][@b40][@b41][@b42][@b43][@b46][@b47] showed the outcomes of OS, which revealed a pooled OS of 73--100% at all stages of follow-up (95.9% at year 1, 94.3 at year 3, 73--98.9% OS at year 5, 91--92% at year 8 and 87% at year 10). Fifteen publications[@b21][@b22][@b24][@b25][@b27][@b29][@b34][@b35][@b36][@b37][@b38][@b41][@b42][@b43][@b47] presented results of 79--100% DSS. Differences between primary and salvage treatment were not clear.

Above all, all studies reported the results of DFS, demonstrating results of 25--95.3% for salvage treatments according to the Phoenix definition for recurrence (PSA nadir +2 ng/ml) (83--95.3% at year 1, 72% at year 2, 59--72.4% at year 3, 25--78% at year 5 and 39% at year 8 and 10). However, a higher trend in DFS results could be found for primary studies (44.6--100% overall: 97.9% at year 1, 77.2% at year 2, 82.9% at year 3, 79.6% at year 4, 48--82.9% at year 5 and 89.5% at year 7). In addition, DFS in two studies[@b33][@b36] were counted on the basis of only positive results for prostatic biopsy, and demonstrated 84--87.6% DFS up to the end of follow-up. Moreover, three papers reported patients receiving both therapies and revealed 68.8--93.3% DFS.

### Secondary outcomes

Reports of complications are not easily summarized. (1) For overall complications, one study[@b36] reported 19% complications, with 16.7% at grade 3--4 according to the Clavien classification by Kvorning Ternov *et al*.[@b43]; (2) for urinary complications, including incontinence, urgency, dysfunction, stricture, fistula, etc., a maximum of \>53.3%[@b43] in total and 41% (increasing) after CS[@b29]; (3) for ED complications, a maximum of 100%[@b43] in total and 56.8% (increasing)[@b23]. Another study[@b29] presented 33.4% (increasing) for level 3 and higher erectile function according to International Index of Erectile Function-5 (IIEF-5) for patients followed with CS. However, Bahn *et al*.[@b25] introduced an investigational and focal CS for patients with a strong desire for the preservation of sexual function, which decreased the frequency of irremediable ED to 11.1%.

Discussion
==========

Over the last few decades, the promotion of screening of PSA for detecting PCa has resulted in a stage migration towards an increase in the occurrence of lower stages, resulting in a controversy regarding the overdetection and overtreatment of PCa. In general, radical therapies, such as RP and radical RT, are regarded as the most effective methods for localized PCa. However, the benefits of these therapies compared with conservative observation remain under debate.

As a compromise between radical treatments and conservation, focal therapy has been applied increasingly as an effective modality for the cure or control of early cancer with minimal injury, especially for patients who cannot tolerate RP or RT. Multiple technologies have been applied for focal therapy, such as CS, high intensity focused ultrasound (HIFU), vascular-targeted photodynamic therapy, etc. Being one of the most popular focal therapies, CS has been applied to a quantity of solid neoplasms and achieved satisfactory outcomes. Four main pathways may have contributed to its mechanism: direct cell injury, vascular injury and ischemia, apoptosis, and immunomodulation[@b48].

The results of initial trials have made CS very popular. However, subsequent controversies on its efficiency, safety and applications surfaced. Up to know, only two RCTs have been conducted which revealed conflicting results. To solve this issue, we tried to explore this meta-analysis and comprehensively systematic review.

Our study results show that DFS observed after CS was significantly lower than that after RP; however, only an insignificant negative was observed compared with RT. More importantly, when parameters of pooled OS, DSS, rates of biopsy positivity and metastasis were evaluated, CS had more satisfactory tendencies, which implied support for its usage regardless of primary or salvage treatment. Furthermore, differences were insignificant for all primary outcomes in sensitivity analysis compared with RT. Similarly, relatively satisfactory results could be achieved from the systematic reviews of databases of large samples and single-arm studies[@b49], although worse results were seemingly revealed in salvage treatments compared with primary procedures.

On the other hand, Simoneau believed that complication rates of CS were acceptable and major complications of CS included urethral sloughing (leading to retention), rectal fistula, incontinence and erectile dysfunction[@b50]. However, pooled data in our analysis showed more complications in the CS group compared with the RT group, in both urinary and sexual bothers. In addition, a relatively large proportion of patients from the systematic review had complications. Furthermore, significantly decreased scores according to UCLA-PCI were also dynamically shown by Malcolm *et al*.[@b51], but these results were unavailable for pooling analysis. However, such adverse events are being decreased with the evolution of new technologies, including penile rehabilitation with a vacuum therapy device[@b52]. Furthermore, salvage CS may be associated with a higher frequency of both urinary and sexual functions than primary CS[@b53], however, this finding could not be validated in our study.

With regard to the choice of primary CS, materials from propensity-weighted analyses revealed that older patients, having one comorbidity, low income, a diagnosis of indolent cancer and lower Gleason scores/D'Amico risk could be more likely to choose CS as an initial treatment[@b17]. Moreover, Nomura *et al*. thought CS could be used in any tumor grade of PCa with clinical stages T1c-T3, in which primary CS is suitable for low-risk patients whereas effective for the intermediate-risk patients[@b54].

Furthermore, Mouraviev *et al*. concluded that CS should be recognized as an established salvage therapeutic option, and patients with serum PSA of \<10 ng/ml, Gleason score of ≤8 and clinical stage of T1c or T2 before therapy are suitable for salvage CS followed by RT[@b55]. Similar beneficial outcomes of salvage CS compared with salvage androgen deprivation therapy were obtained in another RCT[@b56]. In Han's opinion, CS was indicated as an alternative to RP or RT in low-risk patients, as primary therapy in patients with higher surgical risk, and as a salvage procedure in patients who had not responded to RT[@b57]. However, detailed stratifications based on these factors were not presented in our study, which would be its biggest limitation; however, this problem could not have been avoided in the present study.

In our study, seven studies had focused on focal CS while nine studies on whole-gland CS for PCa, which revealed comparable results, even worse results for whole-gland treatment in part of studies, for primary outcomes. However, trends of more patients with advanced PCa could be found in studies using whole-gland CS in further analysis. In theory, whole-gland ablation might capture more favorable survival compared to focal therapy for similar PCa patients as more cancer demised, while more complications must take into consideration. In an age-matched comparison between focal and whole-gland procedures for primary low-risk PCa patents[@b58], comparable 5-year survival and higher erectile function preservation rate could be found in focal therapy group. However, comparison of these two methods for more advanced patients and salvage option need to be further discussed.

Almost half of the publications cited in our study reported the efficacy of primary CS for clinically localized PCa, which revealed overall DFS percentages of 44.6--100%. However, whether recurrence patients experiencing primary CS need to be treated by salvage methods remain unclear except for Chang's study[@b44]. Except for repeat CS, other available options for recurrence include EBRT, RP, endocrine therapy and watchful waiting, of which EBRT would to be the most reasonable choice.

Finally, several important limitations, which might influence the reliability of our results, must be taken into consideration. First, probably because of the relative novelty and limited usage of CS, the pooling results cannot be generalized, considering that only two RCTs and a few comparative studies had focused on CS vs RT/RP. Second, as mentioned above, the stratification factors of PCa, such as PSA level, Gleason score, D'Amico risk classification, clinical stage, was complex, making it very hard for more detailed analysis apart from meta-analysis. Furthermore, because EBRT and BT were merged into the RT group in the meta-analysis, bias could have been generated to a great or lesser extent. Similarly, the results of meta-analysis should be carefully cautioned as large heterogeneity existed, which might be caused by differences between patients, operators, etc. However, to some degree, limitations from these aspects could be supplemented by systematic review. Nonetheless, more accurate results are still urgently required.

In summary, pooling data based on meta-analysis and databases supports the conclusion that CS would be a relatively efficient minimally invasive choice for clinically localized PCa with no significant lower OS, DSS and DFS compared with RT and RP. Similarly favorable results could be also supported in some degree by the systematic review for primary and salvage treatments. However, the large number of adverse events in urinary and genital systems indicates that clinicians should exercise caution and further prove its safety. In future, a more advanced operating system for CS with a lower occurrence of complications is expected. More importantly, more well-designed RCTs and high-quality prospectively comparative studies with long-term follow-up results should be conducted to accurately solve this issue and complete our meta-analysis.

Methods
=======

Literature-search strategy
--------------------------

In March 2016, two reviewers independently carried out a systematic search of three databases---PubMed, Embase and the Cochrane Library for all English literature published on or before December 15 without of any restrictions. The following MeSH terms and their combinations were searched to identify relevant studies in \[Title/Abstract\]: prostate/prostatic, cancer/carcinoma/adenocarcinoma, cryoablation/cryosurgery/cryotherapy/cryotreatment.

Inclusion and exclusion criteria
--------------------------------

All available randomized controlled trials (RCTs) and controlled studies (prospective or retrospective) which had compared primary or salvage CS with RT (external beam radiation therapy \[EBRT\]/brachytherapy \[BT\]) or RP (through open/laparoscopic/robot-assisted approaches) in patients with clinically localized PCa were included in the review. In addition, materials reporting results of CS in single-arm trials were also reviewed systematically. To supplement these data, the related reference lists from identified documents were also acquired, and all computer searches were supplemented with a manual search. When multiple reports described the same population, the most comprehensive or recent was used.

Patients with organ metastasis were excluded. Because of the possibly unavoidable replication with small-scale studies, patients from registered databases were excluded from meta-analysis but were included in the [supplementary systematic review](#S1){ref-type="supplementary-material"}. Finally, data from conference abstracts, papers that were not extractable or whose data were not available for our analyses were also disregarded.

Data extraction and outcomes of interest
----------------------------------------

Data were extracted from the studies and compiled by two reviewers. In the case of any disagreement, a consensus was reached by Yuan after a discussion. Moreover, in the case of studies dividing patients into more than three groups, comparisons between CS and RP or RT were extracted, in which the RP group, including open/laparoscopy/robot-assisted approach, and the RT group, with EBRT/BT, were included. Meanwhile, patients who had experienced total or subtotal CS were included in the CS group. The levels of evidence of all controlled studies were evaluated using the criteria from the Centre for Evidence-Based Medicine in Oxford. However, the blinding method was not analyzed in this review because of its unsuitability for clinical trials of surgical methods.

The primary outcomes were overall survival (OS), disease-specific survival (DSS) and disease-free survival (DFS) of each intervention. The secondary events were complications caused by procedures and obtained through questionnaires, which predominantly included urinary and sexual bothers, mainly erectile dysfunction (ED). Continuous results of urinary and sexual bother scores were recorded according to the University of California Los Angeles, Prostate Cancer Index (UCLA PCI), which measures disease-specific health-related quality of life in six domains: sexual function and sexual bother, urinary function and urinary bother, and bowel function and bowel bother, whereas dichotomous variables were graded according to patients' reporting of moderate to severe urinary and sexual bothers. After summarizing the finding, the rates of biopsy positivity and metastasis were also pooled as secondary outcomes.

Quality assessment and statistical analysis
-------------------------------------------

All the meta-analyses were performed using Review Manager 5.2 (Cochrane Collaboration, Oxford, UK). The weighted mean difference (WMD) and risk ratio (RR) were used to describe results for continuous and dichotomous variables, respectively. For studies that presented medians of follow-up results, the approximate mean was used. All results were reported with 95% confidence intervals (CIs).

Meta-analysis was performed using the random-effects method or the fixed-effects method if significant heterogeneity was not observed. Statistical heterogeneity between trials was evaluated using the I^2^ and chi-square tests with significance set as p values of \<0.10. I^2^ value of 25%, 50% and 75% corresponded to low, medium and high levels of heterogeneity, respectively.
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###### Basic information and characteristics of studies for meta-analysis.

  Author                      Year   Design   Level of evidence   Patients   Freeze-thaw cycle(s)   Mean follow up (Months)   Radiation dose/ Surgical mode  Duration of ADT[\*](#t1-fn1){ref-type="fn"}     Matching                                      Definition of recurrence  Primary or salvage                               
  -------------------------- ------ -------- ------------------- ---------- ---------------------- ------------------------- ------------------------------- ----------------------------------------------- -------------------------------------------- -------------------------- ------------------------------------------------ ---------
  CS vs RT                                                                                                                                                                                                                                                                                                                            
   Ball *et al*.[@b5]         2006     P             2a              39              118                    Double                          6                45 Gy EBRT + 100 Gy BT or 125 Gy BT (Pd -103)   NA                                                 1, 4, 5, 6, 8        NA                                               Both
   Hubosky *et al*.[@b6]      2007     R             3b              63               63                    Double                        12.7               125 Gy BT (Pd -103) or EBRT + BT                NA                                             1, 2, 3, 4, 5, 6, 7, 8   PSA \> 0.4 ng/ml or 3 consecutive rises in PSA   Primary
   Chin *et al*.[@b7]         2008    RCT            1b              33               31                    Double                         37                66 Gy EBRT                                      3 months pre- and 3 months post- treatment     1, 2, 4, 5, 6, , 8, 9    Nadir +2 ng/ml                                   Primary
   Chin *et al*.[@b8]         2012     31            31            105.2                                                                                                                                                                                                                                                              
   Robinson *et al*.[@b9]     2009    RCT            1b             117              114                    Double                         100               \<70/70/73.5 Gy EBRT                            3/6 months pretreatment                        1, 2, 4, 5, 6, 7, 8, 9   PSA \> 0.1 ng/ml or nadir +2 ng/ml               Primary
   Donnelly *et al*.[@b10]                                                                                                                                                                                                                                                                                                            
   Peters *et al*.[@b11]      2013     R             3a              54               31                    Double                      36 vs 108            145 Gy BT (I-125)                               3 months pretreatment                          1, 2, 3, 4, 5, 6, 8, 9   PSA \> 0.1 ng/ml or nadir +2 ng/ml               Salvage
  CS vs RP                                                                                                                                                                                                                                                                                                                            
   Gould[@b12]                1999     R             3b              76               83                      NA                           25                Open                                            NA                                                    1, 3, 4           PSA \> 0.2 ng/ml                                 Primary
   Pisters *et al*.[@b13]     2009     R             3b              56               42               Single and double               66 vs 93.6            NA                                              NA                                                 1, 2, 4, 5, 6        PSA \> 0.4 ng/ml or nadir +2 ng/ml               Salvage
   Peters *et al*.[@b11]      2013     R             3a              54               44                    Double                      36 vs 60             Open                                            ≥3 months. pretreatment                        1, 2, 3, 4, 5, 6, 8, 9   PSA \> 0.1 ng/ml or nadir +2 ng/ml               Salvage
   Elkjær *et al*.[@b14]      2014     P             3b              40              350                    Double                     29.5 vs 37            Open and robot                                  NA                                              1, 2, 3, 4, 5, 6, 7     PSA \> 0.2 ng/ml or nadir +2 ng/ml               Primary

Matching: 1 = age; 2 = inclusion and exclusion criteria; 3 = stratification; 4 = PSA level; 5 = biopsy Gleason score; 6 = clinical stage; 7 = D'Amico risk group; 8 = adjuvant deprivation therapy (ADT) before treatment; 9 =ADT after treatment.

^\*^Not all patients had experienced adjuvant deprivation treatment (ADT) for studies have reported ADT. NA: not available; CS: cryosurgery; RT: radiotherapy; RP: radical prostatectomy; R: retrospective; P: prospective; RCT: randomized controlled trial; EBRT: external beam radiation therapy; BT: brachytherapy; PSA: prostate specific antigen; Pd: palladium; I: iodine.

###### Basic information, characteristics and outcomes of comparative studies using materials from registry databases.

  Author                        Year   Database   Design   Level of evidence          Matching           Mean follow-up (months)   Complications (%)                                                                                                                                          
  ---------------------------- ------ ---------- -------- ------------------- ------ ---------- ------- ------------------------- ------------------- -------------- ---------- ------------------------------------------------------------------------ ------ -------- ------ ------ ------ ------
  White *et al*.[@b15]          2008   CaPSURE      R             3b            12       26       31        1, 2, 4, 6, 8, 9              --                --          51.4     Dynamically changes at years of 1, 2 and 3 according to UCLA PCI score                                       
  Williams *et al*.[@b16]       2011     SEER       P             2a           943      9985      --        1, 2, 4, 6, 8, 10             --                --          \>36                                      65.0                                    48.8    39.2    22.2    --    35.1   21.1
  Roberts *et al*.[@b17]        2012     SEER       R             2b           380     10757     3960      1, 2, 4, 6, 7, 8, 9            --                --          \>12                                       --                                      --    \>28.7    --     --    20.1    --
  Friedlander *et al*.[@b18]    2014     SEER       R             2b           341       --       99         1, 2, 5, 8, 10          93.9 vs 78.4      98.6 vs 93.5   15 vs 30                                     --                                      --      --      --     --     --     --
  Jarosek *et al*.[@b19]        2014     SEER       P             2a           2115    70412     26790        1, 2, 3, 4, 8               --                --          49.7                                       --                                      --     19.4    19.7   27.2    --     --

Matching: 1 = age; 2 = inclusion and exclusion criteria; 3 = matched design; 4 = primary treatment; 5 = salvage treatment; 6 = PSA level; 7 = biopsy Gleason score; 8 = clinical stage; 9 = D'Amico risk group; 10 = adjuvant deprivation therapy (ADT); CaPSURE: the Cancer of the Prostate Strategic Research Endeavor registry; SEER: Surveillance Epidemiology and End Results-Medicare linked database; OS: overall survival; DSS: disease specific survival; UCLA PCI: the University of California Los Angeles, Prostate Cancer Index.

###### Basic information, characteristics and outcomes from single-arm studies.

  Author                            Year   Design   Primary or salvage   Patients      Basic information                   Results (%)                Mean follow-up (months)                 Complications (%)                                                                                                                
  -------------------------------- ------ -------- -------------------- ---------- ------------------------- --------------------------------------- ------------------------- ----------------------------------------------- ------ ------------------------ --------------------------------------------------------------- ------------------------------------------------------------
  Pisters *et al*.[@b20]            1999     R           Salvage           145          5, 6, 7, 8, 10                         --                               --                                  55.2                        \>6              --                                          --                                                             --
  De La Taille *et al*.[@b21]       2000     P             Both             35         1, 2, 5, 6, 7, 10                       100                              100                             70(9 months)                    8.3              --                                         \>8.6                                                           --
  Izawa *et al*.[@b22]              2002     R           Salvage           131            5, 6, 7, 8,                       73(5 yrs)                        79(5 yrs)                            40(5 yrs)                     57.6             --                                                                                                          
  Bahn *et al*.[@b23]               2002     R           Primary           590       1, 2, 5, 6, 7, 8, 10                                                       --                               89.5(7 yrs)                    65.2             --                                        \>15.9                                                     56.8 increased
  Prepelica *et al*.[@b24]          2005     R           Primary            65       1, 2, 5, 6, 7, 9, 10                      100                              100                                 83.3                         35              --                                          --                                                             --
  Bahn *et al*.[@b25]               2006     R           Primary            31            1, 2, 6, 7                          96.8                              100                                 92.9                         70              --                                          --                                                 11.1(potency preservation)
  Ellis *et al*.[@b26]              2007     NA          Primary           416         1, 5, 6, 7, 8, 9                        --                               --                               79.6(4 yrs)                    20.4             --                                          --                                                             --
  Ismail *et al*.[@b27]             2007     P           salvage           100      1, 2, 5, 6, 7, 8, 9, 10                    --                               100             83%(1 yr); 72%(2 yrs); 59%(3 yrs); 25%(5 yrs)   33.5             --                                         \>16                                                            86
  Ng *et al*.[@b28]                 2007     R           Salvage           187         1, 5, 6, 7, 8, 10             97 (5 yrs); 92 (8 yrs)                     --                                   51                          39              --                                         \>39                                                            --
  Diblasio *et al*.[@b29]           2008     R           Primary            78      1, 3, 4, 5, 6, 7, 8, 10   95.9%(1 yr); 94.3(3 yrs); 94.3(5 yrs)             100                97.9%(1 yr); 82.9%(3 yrs); 82.9(5 yrs)       39.8             --                                     41 increased                            33.4 increased for erectile function of 3 level and higher
  Jones *et al*.[@b30]              2008     R           Primary            77            1, 2, 6, 7                           --                               --                                  44.6                        39.0             --                                          --                                                             --
  Truesdale *et al*.[@b31]          2010     R           Primary            77         1,4, 6, 7, 8, 9,                        --                               --                                  72.7                         24              --             Decreased scores according to AUA SI and IIEF-5, respectively                                
  Williams *et al*.[@b32]           2011     R           Salvage           176         1, 5, 6, 7, 8, 10        95(5 yrs); 91(8 yrs); 87(10 yrs)                --                    47(5 yrs); 39(8 yrs); 39(10 yrs)          89.5             --                                          --                                                             --
  Caso *et al*.[@b33]               2012     R           Primary            97        1, 2, 4, 5, 6, 7, 8                      --                               --                              Biopsy: 87.6                     48              --                                          --                                                             --
  Kim *et al*.[@b34]                2012     R           Primary            10            1, 6, 7, 9                           100                              100                                  100                         13              --                                         \>30                                                            --
  Castro Abreu *et al*.[@b35]       2013     R           Salvage            50          1, 6, 7, 8, 10                         100                              100                              78 (5 yrs)                     \>31             --                                          --                                                             --
  Durand *et al*.[@b36]             2013     P           Primary            48      1, 2, 3, 6, 7, 8, 9, 10                    100                              100                              Biopsy: 84                     13.2             19                                No significantdecreased                           Significant decrease in 3 months but in 6 months
  Al Ekish *et al*.[@b37]           2013     R             Both             30         1, 2, 6, 7, 9, 10                       100                              100                                 93.3                         18              --                                          --                                                             --
  Hale *et al*.[@b38]               2013     R           Primary            26         1, 2, 4, 6, 7, 8                        100                              100                                 88.5                        19.1             --                                          --                                                        27 increased
  Ullal *et al*.[@b39]              2013     R             Both             32              1, 6, 7                            --                               --                                  68.8                        41.2             --                                          --                                                             --
  Li *et al*.[@b40]                 2014     R           Salvage            91         1, 2, 6, 7, 8, 10                   98.9(5 yrs)                          --                  95.3(1 yr); 72.4(3 yrs); 46.5(5 yrs)         15              --                                         \>6.6                                                     11.0 increased
  Guo *et al*.[@b41]                2014     R           Primary            75        1, 2, 5, 6, 7, 8, 9                  85.3(5 yrs)                      92.0(5 yrs)                           48(5 yrs)                      75              --                                          --                                                             --
  Rodríguez *et al*.[@b42]          2014     P           Primary           102       1, 5, 6, 7, 8, 9, 10                     94.4                             98.1                                 76.9                         61            \>11.1                                       \>5.6                                                     32.1 increased
  Kvorning Ternov *et al*.[@b43]    2014     R           Salvage            30       1, 2, 6, 7, 8, 9, 10                     93.3                             96.7                                 43.5                        32.4   16.7 for grade 3 and 4                              \>53.3                                                          100
  Chang *et al*.[@b44]              2014     R           Salvage            12         1, 2, 6, 7, 8, 10                       --                               100                                 58.3                         33              --                                         16.7                                                           16.7
  Elshafei *et al*.[@b45]           2015     R           Primary           2242       1, 2, 4, 5, 7, 8, 9                      --                               --                               72.8(5yrs)                     32.6             --                                          --                                                             --
  Tay *et al*.[@b46]                2016     R           Primary           300       1, 2, 6, 7, 8, 9, 10                     96.7                              --                         77.2(2yrs), 59.1(5yrs)               28.4             --                                         \>9.7                                                          83.5
  Lian *et al*.[@b47]               2016     R           Primary            40      1, 2, 5, 6, 7, 8, 9, 10                    100                              100                                  95                          63              --                                          --                                                            36.6

Matching: 1 = age; 2 = inclusion and exclusion criteria; 3 = body mass index (BMI); 4 = race; 5 = stratification; 6 = PSA level; 7 = biopsy Gleason score; 8 = clinical stage; 9 = D'Amico risk group; 10 = adjuvant deprivation therapy (ADT); bDFS: biochemical disease free survival; ED: erectile dysfunction; AUA SI: American Urological Association Symptom Index; IIEF: International Index of Erectile Function; IPSS: International Prostate Symptom Score; yrs: years.

[^1]: These authors contributed equally to this work.
